SynaptixBio Ltd gets FDA ODD for leukodystrophy
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1391 entries already.
Entries by Thomas Gabrielczyk
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
/in News/by Thomas GabrielczykPierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Bayer SE secures rights to in €310m deal
/in News/by Thomas GabrielczykBayer AG has purchased European commercialisation rights for the transthyretin amyloid cardiomyopathy candidate acoramidis from BridgeBio Inc.<i> </i>
Swiss vaccine developer Limma Tech get CARB-X grant
/in News/by Thomas GabrielczykSwiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Curve Therapeutics raises £40.5m in Series A financing
/in News/by Thomas GabrielczykIntracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
Pacifico Biolabs raises US$3.3m in pre-seed round
/in News/by Thomas GabrielczykGerman foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.<br /><br /><br /><br />
Gene therapy supplier MIP Discovery closes £7M Series A financing
/in News/by Thomas GabrielczykMIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
Vidac Pharma Holding plc reports preclinical proof of principle
/in News/by Thomas GabrielczykLondon-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.
Roche leads Freenome Inc US$257m financing
/in News/by Thomas GabrielczykMulti-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection […]
Bioplastics production capacity to quadruple by 2028
/in News/by Thomas GabrielczykNew figures published by the industry association European Bioplastics suggest a sharp increase in the production of sustainable plastics in the next two years and calls for policy support.